Read from Anita Moser, Michael Davis, Dharmendra Sahay as they outline UCB's measured approach to scaling our AI capabilities. The article was originally published in PharmExec.

UCB enters into collaboration with Roche to develop antibody treatment for people living with Alzheimer’s Disease

At UCB, we know to successfully bring value to the lives of patients we need to cultivate a healthy and connected culture within. This is why UCB provides its employees at its U.S. Headquarters in Atlanta, Georgia and across the U.S. with the tools and facilities to prioritize their well-being.

Bimekizumab Superior to Cosentyx® in Achieving Complete Psoriasis Skin Clearance

Today, UCB issued the following statement jointly from Camille Lee, Head of U.S. Immunology, and Jeff Stark, M.D., Head of U.S. Medical Immunology, on the recent update by the ICD-10 Coordination and Maintenance Committee (a subcommittee of the U.S. Centers for Disease Control and Prevention) to endorse and make public that non-radiographic axial spondyloarthritis (nr-axSpA) will be formally indexed to ICD-10 sub category M46.8; these changes will be effective for diagnoses starting October 1, 2020 and more information is available on the Centers for Medicare & Medicaid Service (CMS) website which outlines the specific coding changes in greater detail:

At UCB, patients are at the heart of everything we do. Read more from Brad Chapman, U.S. Head of Internal Operations and West Ecosystem - Neurology, on how our agile ways of working are helping us keep our commitment to patients, physicians, and the communities we serve in a work-from-home world.

Despite the unprecedented events stemming from the novel coronavirus, we are pleased to continue our mission of investing in the next generation of the work force by welcoming 18 student interns to our first virtual internship program.

UCB and Ferring Pharmaceuticals Announce Co-Promotion of CIMZIA^® (certolizumab pegol) for the Treatment of Adults with Moderate to Severe Crohn’s Disease